Pro-Dex, Inc. Director Sells $50,000 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) recently saw its Director, Raymond E. Cabillot, sell 1,000 shares of the company's stock. This transaction took place on Wednesday, March 19th, and the shares were sold at an average price of $50.00, resulting in a total sale of $50,000. Following this sale, Cabillot now directly owns 299,695 shares in Pro-Dex, which amounts to a value of approximately $14,984,750. This sale represents a 0.33% decrease in his holdings. The details of this transaction were disclosed in a legal filing with the Securities and Exchange Commission (SEC), which can be accessed at this link.

Pro-Dex Price Performance

During midday trading on Friday, shares of Pro-Dex (NASDAQ:PDEX) dipped by $0.13, reaching a price of $48.92. In total, 14,151 shares were traded, which is less than the average volume of 21,678 shares. The company's stock has a 50-day moving average price of $39.74 and a 200-day moving average price of $38.81. Pro-Dex has a current market capitalization of $159.53 million, a price-to-earnings (P/E) ratio of 24.34, and a beta of 0.68. Over the past year, the stock has fluctuated between a low of $16.84 and a high of $59.60. The company's quick ratio stands at 1.44, the current ratio at 2.58, and the debt-to-equity ratio at 0.33.

Pro-Dex last published its earnings results on Thursday, January 30th. The company, which supplies medical instruments, reported an earnings per share (EPS) of $0.61 for the quarter, exceeding analysts' expectations of $0.38 by $0.23. Pro-Dex also reported a net margin of 11.06% and a return on equity of 21.68%. Analysts predict that Pro-Dex will generate an EPS of 2 for the current fiscal year.

Analysts Set New Price Targets

In related news, StockNews.com recently downgraded Pro-Dex from a "buy" rating to a "hold" rating in a research note published on Wednesday, March 12th.

Read Our Latest Research Report on PDEX

Hedge Funds Weigh In On Pro-Dex

Various hedge funds have recently adjusted their holdings of Pro-Dex. EAM Investors LLC purchased a new position worth $1,047,000 in shares of Pro-Dex during the fourth quarter. Other institutions such as O'Shaughnessy Asset Management LLC and 683 Capital Management LLC also entered new positions worth $995,000 and $739,000 respectively. Ritholtz Wealth Management and American Century Companies Inc. bought new stakes worth $572,000 and $558,000 respectively. Institutional investors and hedge funds collectively own 15.28% of the company’s stock.

About Pro-Dex

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers across the globe. Their product range includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used primarily in orthopedic, thoracic, and craniomaxillofacial surgeries.

See Also

• Five stocks we like better than Pro-Dex
• How to Plot Fibonacci Price Inflection Levels
• FedEx Delivers Another Crushing Blow to Its Stock Price
• Unveiling The Power Of VWAP: A Key Indicator For Traders
• Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
• How to Most Effectively Use the MarketBeat Earnings Screener
• Micron Stock Will Retest All-Time Highs This Year

This article is generated for informative purposes.

Should You Invest $1,000 in Pro-Dex Right Now?

Before making any investment decisions regarding Pro-Dex, it is essential to assess current market recommendations from top analysts. While the company holds a "Buy" rating among analysts, many believe there are more compelling investment opportunities available. It may be beneficial to review recent top picks to make an informed decision.

Pro-Dex, stocks, director